COMPUGEN-CPG-02-101
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
DAIICHI-DS1062-A-U304
Phase III
OPEN TO ACCRUAL
A Randomized, Open-Label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >/= 50%) Non-Small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung08)
GENMAB-GCT1046-04
Phase II
OPEN TO ACCRUAL
A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment with Standard of Care Therapy with an Immune Checkpoint Inhibitor
MABSPACE-TST001-1001
Phase I/II
OPEN TO ACCRUAL
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
NRG-GY022
Phase I
OPEN TO ACCRUAL
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
SWOG-LUNGMAP
Phase II/III
OPEN TO ACCRUAL
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
TAIHO-TAS6417-201
Phase II
OPEN TO ACCRUAL
An Open-Label, Phase 2b, Global Multi-Center Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertions and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations